Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia

Background: Cytogenetics at diagnosis is the most important prognostic factor for adult acute myeloid leukemia (AML), but nearly 50% of AML patients who exhibit cytogenetically normal AML (CN-AML) do not undergo effective risk stratification. Therefore, the development of potential biomarkers to fur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cunte Chen MD, Zhuowen Chen MD, Chi Leong Chio MD, Ying Zhao MD, Yongsheng Li MM, Zhipeng Liu MM, Zhenyi Jin MD, Xiuli Wu MD, Wei Wei PhD, Qi Zhao PhD, Yangqiu Li MD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a692c929daee4ec78762d83b04da202e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a692c929daee4ec78762d83b04da202e
record_format	dspace
spelling	oai:doaj.org-article:a692c929daee4ec78762d83b04da202e2021-11-05T22:33:31ZHigher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia1533-033810.1177/15330338211052152https://doaj.org/article/a692c929daee4ec78762d83b04da202e2021-11-01T00:00:00Zhttps://doi.org/10.1177/15330338211052152https://doaj.org/toc/1533-0338Background: Cytogenetics at diagnosis is the most important prognostic factor for adult acute myeloid leukemia (AML), but nearly 50% of AML patients who exhibit cytogenetically normal AML (CN-AML) do not undergo effective risk stratification. Therefore, the development of potential biomarkers to further define risk stratification for CN-AML patients is worth exploring. Methods: Transcriptome data from 163 cases in the GSE12417-GPL96 dataset and 104 CN-AML patient cases in the GSE71014-GPL10558 dataset were downloaded from the Gene Expression Omnibus database for overall survival (OS) analysis and validation. Results: The combination of Wilms tumor 1 ( WT1 ) and cluster of diffraction 58 ( CD58 ) can predict the prognosis of CN-AML patients. High expression of WT1 and low expression of CD58 were associated with poor OS in CN-AML. Notably, when WT1 and CD58 were used to concurrently predict OS, CN-AML patients were divided into three groups: low risk, WT1 low CD58 high ; intermediate risk, WT1 high CD58 high or WT1 low CD58 low ; and high risk, WT1 high CD5 8 low . Compared with low-risk patients, intermediate- and high-risk patients had shorter survival time and worse OS. Furthermore, a nomogram model constructed with WT1 and CD58 may personalize and reveal the 1-, 2-, 3-, 4-, and 5-year OS rate of CN-AML patients. Both time-dependent receiver operating characteristics and calibration curves suggested that the nomogram model demonstrated good performance. Conclusion: Higher expression of WT1 with lower CD58 expression may be a potential biomarker for risk stratification of CN-AML patients. Moreover, a nomogram model constructed with WT1 and CD58 may personalize and reveal the 1-, 2-, 3-, 4-, and 5-year OS rates of CN-AML patients.Cunte Chen MDZhuowen Chen MDChi Leong Chio MDYing Zhao MDYongsheng Li MMZhipeng Liu MMZhenyi Jin MDXiuli Wu MDWei Wei PhDQi Zhao PhDYangqiu Li MDSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTechnology in Cancer Research & Treatment, Vol 20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Cunte Chen MD Zhuowen Chen MD Chi Leong Chio MD Ying Zhao MD Yongsheng Li MM Zhipeng Liu MM Zhenyi Jin MD Xiuli Wu MD Wei Wei PhD Qi Zhao PhD Yangqiu Li MD Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia
description	Background: Cytogenetics at diagnosis is the most important prognostic factor for adult acute myeloid leukemia (AML), but nearly 50% of AML patients who exhibit cytogenetically normal AML (CN-AML) do not undergo effective risk stratification. Therefore, the development of potential biomarkers to further define risk stratification for CN-AML patients is worth exploring. Methods: Transcriptome data from 163 cases in the GSE12417-GPL96 dataset and 104 CN-AML patient cases in the GSE71014-GPL10558 dataset were downloaded from the Gene Expression Omnibus database for overall survival (OS) analysis and validation. Results: The combination of Wilms tumor 1 ( WT1 ) and cluster of diffraction 58 ( CD58 ) can predict the prognosis of CN-AML patients. High expression of WT1 and low expression of CD58 were associated with poor OS in CN-AML. Notably, when WT1 and CD58 were used to concurrently predict OS, CN-AML patients were divided into three groups: low risk, WT1 low CD58 high ; intermediate risk, WT1 high CD58 high or WT1 low CD58 low ; and high risk, WT1 high CD5 8 low . Compared with low-risk patients, intermediate- and high-risk patients had shorter survival time and worse OS. Furthermore, a nomogram model constructed with WT1 and CD58 may personalize and reveal the 1-, 2-, 3-, 4-, and 5-year OS rate of CN-AML patients. Both time-dependent receiver operating characteristics and calibration curves suggested that the nomogram model demonstrated good performance. Conclusion: Higher expression of WT1 with lower CD58 expression may be a potential biomarker for risk stratification of CN-AML patients. Moreover, a nomogram model constructed with WT1 and CD58 may personalize and reveal the 1-, 2-, 3-, 4-, and 5-year OS rates of CN-AML patients.
format	article
author	Cunte Chen MD Zhuowen Chen MD Chi Leong Chio MD Ying Zhao MD Yongsheng Li MM Zhipeng Liu MM Zhenyi Jin MD Xiuli Wu MD Wei Wei PhD Qi Zhao PhD Yangqiu Li MD
author_facet	Cunte Chen MD Zhuowen Chen MD Chi Leong Chio MD Ying Zhao MD Yongsheng Li MM Zhipeng Liu MM Zhenyi Jin MD Xiuli Wu MD Wei Wei PhD Qi Zhao PhD Yangqiu Li MD
author_sort	Cunte Chen MD
title	Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia
title_short	Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia
title_full	Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia
title_fullStr	Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia
title_full_unstemmed	Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia
title_sort	higher expression of with lower expression may be biomarkers for risk stratification of patients with cytogenetically normal acute myeloid leukemia
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/a692c929daee4ec78762d83b04da202e
work_keys_str_mv	AT cuntechenmd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT zhuowenchenmd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT chileongchiomd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT yingzhaomd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT yongshenglimm higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT zhipengliumm higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT zhenyijinmd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT xiuliwumd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT weiweiphd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT qizhaophd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT yangqiulimd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia
_version_	1718443998549377024

Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia

Ejemplares similares